XML 18 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 49,101 $ 28,834 $ 89,538 $ 58,312
Selling, general and administrative 14,730 12,745 29,941 24,143
Total operating expenses 63,831 41,579 119,479 82,455
Loss from operations (63,831) (41,579) (119,479) (82,455)
Other income (expense):        
Research and development incentives 443 574 836 1,425
Investment income 6,049 1,112 12,235 1,455
Interest expense on finance lease liability (542) (550) (1,086) (1,102)
Interest expense on debt obligations (955) 0 (2,070) 0
Other (expense) income (1,409) (2,659) (35) (4,678)
Total other income (expense), net 3,586 (1,523) 9,880 (2,900)
Loss before income taxes (60,245) (43,102) (109,599) (85,355)
Income tax (benefit) (201) 0 0 0
Net loss $ (60,044) $ (43,102) $ (109,599) $ (85,355)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.90) $ (0.79) $ (1.65) $ (1.57)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.90) $ (0.79) $ (1.65) $ (1.57)
Weighted average common shares outstanding, basic (in shares) 66,582,280 54,770,291 66,475,577 54,492,395
Weighted average common shares outstanding, diluted (in shares) 66,582,280 54,770,291 66,475,577 54,492,395